$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000155837020010225 Filed on August 10, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q2
Revenue	$38.00K	$38.00K	$38.00K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$35.30M	$14.43M	$2.720M
YoY Change	1112.92%	430.66%	-52.11%
% of Gross Profit
Research & Development	$50.46M	$36.45M	$32.87M
YoY Change	-12.97%	10.9%	-15.07%
% of Gross Profit
Depreciation & Amortization	$50.00K	$30.00K	$30.00K
YoY Change	150.0%	0.0%	50.0%
% of Gross Profit
Operating Expenses	$85.76M	$50.88M	$35.58M
YoY Change	40.82%	43.0%	-19.83%
Operating Profit	-$85.72M	-$50.85M	-$35.54M
YoY Change	40.85%	43.05%	-180.15%
Interest Expense	$1.610M	$2.228M	$1.077M
YoY Change	4.75%	106.87%	466.84%
% of Operating Profit
Other Income/Expense, Net	-$1.441M	-$2.039M	-$669.0K
YoY Change	34.8%	204.78%	-429.56%
Pretax Income	-$87.16M	-$52.88M	-$36.21M
YoY Change	40.74%	46.04%	-17.97%
Income Tax
% Of Pretax Income
Net Earnings	-$87.16M	-$52.88M	-$36.21M
YoY Change	40.74%	46.04%	-17.96%
Net Earnings / Revenue	-229376.32%	-139168.42%	-95297.37%
Basic Earnings Per Share
Diluted Earnings Per Share	-$731.3K	-$470.7K	-$417.2K
COMMON SHARES
Basic Shares Outstanding	126.6M	113.7M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$254.2M	$275.6M	$85.00M
YoY Change	250.62%	224.24%	-32.65%
Cash & Equivalents	$254.2M	$260.5M	$57.23M
Short-Term Investments	$0.00	$15.10M	$27.70M
Other Short-Term Assets	$641.0K	$1.536M	$987.0K
YoY Change	-25.81%	55.62%	-89.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$260.3M	$280.9M	$94.44M
YoY Change	223.98%	197.47%	-30.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$378.0K	$331.0K	$237.0K
YoY Change	37.45%	39.66%	-90.88%
Goodwill	$799.0K	$799.0K	$799.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.300M	$1.300M	$1.200M
YoY Change	8.33%	8.33%	0.0%
Total Long-Term Assets	$13.52M	$13.68M	$12.14M
YoY Change	4.23%	12.67%	158.38%
TOTAL ASSETS
Total Short-Term Assets	$260.3M	$280.9M	$94.44M
Total Long-Term Assets	$13.52M	$13.68M	$12.14M
Total Assets	$273.9M	$294.6M	$106.6M
YoY Change	193.44%	176.42%	-24.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.70M	$29.70M	$31.50M
YoY Change	9.12%	-5.71%	-11.02%
Accrued Expenses	$6.700M	$5.100M	$3.000M
YoY Change	52.27%	70.0%	150.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.59M	$7.200M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$77.67M	$67.54M	$55.97M
YoY Change	-3.15%	20.67%	51.67%
LONG-TERM LIABILITIES
Long-Term Debt	$15.07M	$22.23M	$28.51M
YoY Change	-47.55%	-22.03%
Other Long-Term Liabilities	$10.50M	$10.60M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$15.07M	$22.23M	$28.51M
YoY Change	-47.55%	-22.03%	1088.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.67M	$67.54M	$55.97M
Total Long-Term Liabilities	$15.07M	$22.23M	$28.51M
Total Liabilities	$103.2M	$100.4M	$93.38M
YoY Change	-13.36%	7.51%	137.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$892.4M	-$805.2M	$599.7M
YoY Change	34.88%	-234.26%
Common Stock	$129.0K	$127.0K	$93.00K
YoY Change	32.99%	36.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$234.0K	$234.0K	$234.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares	$41.31K	$41.31K	41.31K shares
Shareholders Equity	$170.7M	$194.2M	$13.20M
YoY Change
Total Liabilities & Shareholders Equity	$273.9M	$294.6M	$106.6M
YoY Change	193.44%	176.42%	-24.25%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$87.16M	-$52.88M	-$36.21M
YoY Change	40.74%	46.04%	-17.96%
Depreciation, Depletion And Amortization	$50.00K	$30.00K	$30.00K
YoY Change	150.0%	0.0%	50.0%
Cash From Operating Activities	-$56.53M	-$43.83M	-$35.86M
YoY Change	70.27%	22.23%	4.88%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$40.00K	-$20.00K
YoY Change	28.57%	100.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$15.00M	$11.25M	$470.0K
YoY Change	74900.0%	2293.62%	-91.64%
Cash From Investing Activities	$14.91M	$11.21M	$460.0K
YoY Change	-37375.0%	2336.96%	-91.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	35.27M	241.1M	28.28M
YoY Change	70.39%	752.51%	-45.64%
NET CHANGE
Cash From Operating Activities	-56.53M	-43.83M	-35.86M
Cash From Investing Activities	14.91M	11.21M	460.0K
Cash From Financing Activities	35.27M	241.1M	28.28M
Net Change In Cash	-6.350M	208.5M	-7.120M
YoY Change	-49.36%	-3027.95%	-130.4%
FREE CASH FLOW
Cash From Operating Activities	-$56.53M	-$43.83M	-$35.86M
Capital Expenditures	-$90.00K	-$40.00K	-$20.00K
Free Cash Flow	-$56.44M	-$43.79M	-$35.84M
YoY Change	70.36%	22.18%	4.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1136000
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-52884000
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Entity Central Index Key EntityCentralIndexKey	0001001316
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32639
	dei	Entity Registrant Name EntityRegistrantName	TG THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Gansevoort Street, 9th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10014
	dei	City Area Code CityAreaCode	212
	dei	Local Phone Number LocalPhoneNumber	554-4484
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	TGTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	126649205
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260512000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112637000
CY2020Q2	us-gaap	Goodwill Goodwill	799000
CY2019Q4	us-gaap	Goodwill Goodwill	799000
CY2020Q2	us-gaap	Assets Assets	294621000
CY2019Q4	us-gaap	Assets Assets	163014000
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29670000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30041000
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25572000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	48994000
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7200000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1655000
CY2020Q2	tgtx	Leasehold Interest LeaseholdInterest	2157000
CY2019Q4	tgtx	Leasehold Interest LeaseholdInterest	2129000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	331000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	282000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9141000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9402000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1616000
CY2020Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	3440000
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	15058000
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	27798000
CY2020Q2	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	3832000
CY2019Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	8105000
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1536000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	611000
CY2020Q2	us-gaap	Assets Current AssetsCurrent	280938000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	149151000
CY2020Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1255000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1251000
CY2019Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	3798000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	67537000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	84449000
CY2020Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	686000
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	762000
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22233000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28970000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9938000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10218000
CY2020Q2	us-gaap	Liabilities Liabilities	100394000
CY2019Q4	us-gaap	Liabilities Liabilities	124399000
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126690514
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109425243
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126649205
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109383934
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	127000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	109000
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	999549000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	739956000
CY2020Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	41309
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309
CY2020Q2	us-gaap	Treasury Stock Value TreasuryStockValue	234000
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	234000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805215000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-701216000
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	194227000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38615000
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294621000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	163014000
CY2020Q2	us-gaap	Revenues Revenues	38000
CY2019Q2	us-gaap	Revenues Revenues	38000
	us-gaap	Revenues Revenues	76000
	us-gaap	Revenues Revenues	76000
CY2019Q2	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	100000
	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	100000
CY2020Q2	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	1553000
CY2019Q2	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	1352000
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	3532000
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	2841000
CY2020Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	34896000
CY2019Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	31414000
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	68939000
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	62310000
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36449000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32866000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72471000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65251000
CY2020Q2	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	5817000
CY2019Q2	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	405000
	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	14906000
	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	797000
CY2020Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	8617000
CY2019Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2311000
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	13789000
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	4260000
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14434000
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2716000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28695000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5057000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	50883000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	35582000
	us-gaap	Operating Expenses OperatingExpenses	101166000
	us-gaap	Operating Expenses OperatingExpenses	70308000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-50845000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35544000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-101090000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-70232000
CY2020Q2	us-gaap	Interest Expense InterestExpense	2228000
CY2019Q2	us-gaap	Interest Expense InterestExpense	1077000
	us-gaap	Interest Expense InterestExpense	3429000
	us-gaap	Interest Expense InterestExpense	1851000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2910000
CY2020Q2	us-gaap	Other Income OtherIncome	189000
CY2019Q2	us-gaap	Other Income OtherIncome	408000
	us-gaap	Other Income OtherIncome	519000
	us-gaap	Other Income OtherIncome	715000
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2039000
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-669000
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86800017
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	108926690
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84002700
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24036000
CY2019Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	993000
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-36213000
	us-gaap	Profit Loss ProfitLoss	-104000000
	us-gaap	Profit Loss ProfitLoss	-71368000
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.95
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112353414
CY2019Q1	tgtx	Offering Costs At Market OfferingCostsAtMarket	200000
CY2019Q1	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	27499000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1882000
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-35156000
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19254000
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11000
CY2019Q2	tgtx	Offering Costs At Market OfferingCostsAtMarket	1400000
CY2019Q2	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	28395000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1757000
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13205000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38615000
CY2020Q1	tgtx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	80000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11068000
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-51116000
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1353000
CY2020Q2	tgtx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	16000
CY2020Q2	tgtx	Offering Costs OfferingCosts	10900000
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	165042000
CY2020Q2	tgtx	Offering Costs At Market OfferingCostsAtMarket	1400000
CY2020Q2	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	76036000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7370000
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-52884000
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	194227000
	us-gaap	Profit Loss ProfitLoss	-104000000
	us-gaap	Profit Loss ProfitLoss	-71368000
	us-gaap	Share Based Compensation ShareBasedCompensation	18438000
	us-gaap	Share Based Compensation ShareBasedCompensation	3639000
	tgtx	Noncash Licensing Expense NoncashLicensingExpense	100000
	us-gaap	Depreciation Depreciation	64000
	us-gaap	Depreciation Depreciation	46000
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	69000
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	149000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	463000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	308000
	us-gaap	Amortization Of Lease Incentives AmortizationOfLeaseIncentives	110000
	us-gaap	Amortization Of Lease Incentives AmortizationOfLeaseIncentives	91000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2455000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	902000
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-152000
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-78000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3211000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-572000
	tgtx	Increase Decrease In Leasehold Interest IncreaseDecreaseInLeaseholdInterest	91000
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-41000
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	10000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-728000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-5588000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2436000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-678000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-110000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	443000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-23464000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2388000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-105949000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69211000
	tgtx	Proceeds From Maturities ProceedsFromMaturities	20250000
	tgtx	Proceeds From Maturities ProceedsFromMaturities	13500000
	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	7482000
	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	14146000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12655000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-678000
	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	241077000
	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	55965000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	96000
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	29679000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	480000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	241173000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85164000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	147879000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15275000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113888000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43199000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	261767000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58474000
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260512000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57228000
CY2020Q2	us-gaap	Restricted Cash RestrictedCash	1255000
CY2019Q2	us-gaap	Restricted Cash RestrictedCash	1246000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	261767000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58474000
	us-gaap	Interest Paid Net InterestPaidNet	1555000
	us-gaap	Interest Paid Net InterestPaidNet	1051000
	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	60000
	tgtx	Accrued Financing Costs AccruedFinancingCosts	988000
	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	993000
	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	100000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805200000
CY2020Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	275600000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
CY2020Q2	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	1300000
CY2019Q4	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	1300000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2020Q2	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	3800000
CY2019Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	8100000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10535748
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10535748
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7844712
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7844712
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10535748
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7844712
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260512000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112637000
CY2020Q2	us-gaap	Cash Cash	245054000
CY2019Q4	us-gaap	Cash Cash	110135000
CY2020Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	15458000
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2502000
CY2020Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	15058000
CY2020Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	26000
CY2020Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	0
CY2020Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	15084000
CY2019Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	27798000
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	28000
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	0
CY2019Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	27826000
CY2020Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	343000
CY2020Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	343000
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	190000
CY2019Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	190000
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	343000
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	190000
	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	484000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-331000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.8691
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.9105
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.7299
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	2.9161
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0034
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0054
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0196
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0249
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	6975000
	us-gaap	Restricted Stock Expense RestrictedStockExpense	14095000
CY2020Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	395000
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4343000
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	7370000
	us-gaap	Share Based Compensation ShareBasedCompensation	18438000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	147058
CY2019Q4	tgtx	Warrant Or Right Outstanding Weighted Average Exercise Price WarrantOrRightOutstandingWeightedAverageExercisePrice	4.08
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	1032347000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0
	tgtx	Warrant Or Right Issued Weighted Average Exercise Price WarrantOrRightIssuedWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0
	tgtx	Warrant Or Right Exercised Weighted Average Exercise Price WarrantOrRightExercisedWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	0
	tgtx	Warrant Or Right Expired Weighted Average Exercise Price WarrantOrRightExpiredWeightedAverageExercisePrice	0
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	147058
CY2020Q2	tgtx	Warrant Or Right Outstanding Weighted Average Exercise Price WarrantOrRightOutstandingWeightedAverageExercisePrice	4.08
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	2264693000
CY2020Q2	us-gaap	Notes Payable Current NotesPayableCurrent	343000
CY2020Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2020Q2	us-gaap	Notes Payable NotesPayable	343000
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	190000
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2019Q4	us-gaap	Notes Payable NotesPayable	190000
	tgtx	Cumulative Liability Of Note CumulativeLiabilityOfNote	19800000
CY2019	tgtx	Cumulative Liability Of Note CumulativeLiabilityOfNote	19300000
	tgtx	Agreement Costs Aggregate AgreementCostsAggregate	51800000
CY2020Q2	us-gaap	Construction Contract Cost Progress Payment Offset ConstructionContractCostProgressPaymentOffset	27000000.0
	tgtx	Agreement Costs Current Liabilities AgreementCostsCurrentLiabilities	24800000
	tgtx	Agreement Costs Non Current Liabilities AgreementCostsNonCurrentLiabilities	0
	tgtx	Percentage Of Administrative Fee PercentageOfAdministrativeFee	0.06
	tgtx	Interest Expense Recognized As Administrative Fees InterestExpenseRecognizedAsAdministrativeFees	2200000
CY2020Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	30000000
CY2020Q2	tgtx	End Of Term Fee EndOfTermFee	975000
CY2020Q2	tgtx	Long Term Debt Gross LongTermDebtGross	30975000
CY2020Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1542000
CY2020Q2	us-gaap	Long Term Debt LongTermDebt	29433000
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7200000
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22233000
CY2020Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	570000
	us-gaap	Operating Lease Cost OperatingLeaseCost	1077000
CY2020Q2	us-gaap	Lease Cost LeaseCost	570000
	us-gaap	Lease Cost LeaseCost	1077000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1655000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9938000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	11593000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	948000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1889000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1911000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1913000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1796000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	10615000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19072000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7479000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	11593000

Files In Submission

Name	View Source	Status
0001558370-20-010225-index-headers.html	Edgar Link	pending
0001558370-20-010225-index.html	Edgar Link	pending
0001558370-20-010225.txt	Edgar Link	pending
0001558370-20-010225-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20200630.xsd	Edgar Link	pending
tgtx-20200630x10q.htm	Edgar Link	pending
tgtx-20200630x10q_htm.xml	Edgar Link	completed
tgtx-20200630xex31d1.htm	Edgar Link	pending
tgtx-20200630xex31d2.htm	Edgar Link	pending
tgtx-20200630xex32d1.htm	Edgar Link	pending
tgtx-20200630xex32d2.htm	Edgar Link	pending
tgtx-20200630_cal.xml	Edgar Link	unprocessable
tgtx-20200630_def.xml	Edgar Link	unprocessable
tgtx-20200630_lab.xml	Edgar Link	unprocessable
tgtx-20200630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2020 Q3 Form 10-Q Financial Statement

#000155837020010225 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2020 Q3 Form 10-Q Financial Statement

#000155837020010225 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx